Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Signaturefd LLC

Signaturefd LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,126 shares of the biopharmaceutical company’s stock after buying an additional 54 shares during the quarter. Signaturefd LLC’s holdings in Regeneron Pharmaceuticals were worth $1,867,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Sunbelt Securities Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $25,000. Fortitude Family Office LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $31,000. Bruce G. Allen Investments LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $40,000. Finally, Sutton Wealth Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 13 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.3 %

REGN stock traded up $2.83 during mid-day trading on Friday, reaching $896.82. The company had a trading volume of 507,466 shares, compared to its average volume of 412,356. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The company has a market capitalization of $98.43 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11. The firm has a fifty day simple moving average of $953.01 and a 200 day simple moving average of $891.67. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter last year, the company earned $10.96 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total value of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Insiders have sold 13,729 shares of company stock valued at $13,124,641 in the last quarter. Corporate insiders own 8.83% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of several research reports. Royal Bank of Canada reiterated an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. UBS Group upped their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price for the company. Finally, Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $976.41.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.